Latest Data for Regeneron's (REGN) Dupilumab Broadens Benefit Profile - Roth
Tweet Send to a Friend
Roth Capital affirms Regeneron (Nasdaq: REGN) at Buy with a price target of $422 after the company and Sanofi reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
